Abstract 76P
Background
The ClearCell® FX system (FX) is a novel label-free inertial microfluidic CTC isolation platform, in contrast to the EpCAM-based CELLSEARCH® system (CS). We hypothesise that label-free CTC capture will lead to more accurate assessment of CTCs, including PD-L1 expression, and capture CTCs that have undergone epithelial-mesenchymal transition, which is prevalent in advanced cancers.
Methods
CellTrackerTM labelled EpCAM-high and EpCAM-low cell lines were spiked into healthy volunteer (HV) blood, prior to recovery on FX or CS platforms for initial validation studies. Blood samples were then obtained from pts with advanced non-small cell lung (NSCLC), prostate, ovarian, rectal and breast cancers for CTC isolation on FX and CS. CTCs captured on FX were assessed with 5-color immunofluorescence (IF) (CK, CD45, DAPI, PD-L1, as well as TTF-1 [lung adenocarcinoma], androgen receptor [AR; prostate cancer] or EpCAM [other cancers]). HV blood samples were assessed on FX and CS as controls.
Results
FX and CS captured similar counts in EpCAM-high cell lines (FX 67% ± 11 vs CS 74% ± 10 [p = 0.11]). In contrast, higher cell counts were seen with EpCAM-low cell lines with FX vs CS [62% ± 8 vs 32% ± 9 [p
Conclusions
Higher CTC counts were isolated with FX vs CS in 86% of pts. CTC PD-L1 heterogeneity was observed and may in part explain differences in antitumor responses to PD-1/PD-L1 inhibitors. Clinical qualification of this 5-color IF PD-L1 CTC assay is ongoing in a PD-1 inhibitor NSCLC trial.
Clinical trial identification
CCR-2472 study opened 2nd August 2004 CCR-3171 study opened 22nd May 2009
Legal entity responsible for the study
The Institute of Cancer Research. The Royal Marsden Hospital
Funding
ClearBridge Biomedics
Disclosure
T.A. Yap: Funding for this research project is provided by ClearBridge Biomedics. All other authors have declared no conflicts of interest.
Resources from the same session
Utility of algorithm-based chemoradioselection for advanced laryngeal and hypopharyngeal carcinoma
Presenter: Muneyuki Masuda
Session: Poster display
Resources:
Abstract
Utility of a targeted NGS oncology assay for circulating tumor DNA in a multi-histology clinical setting
Presenter: Tera Eerkes
Session: Poster display
Resources:
Abstract
Uterine carcinosarcoma: a retrospective clinical cohort analysis
Presenter: Carla Perna
Session: Poster Display
Resources:
Abstract
Using mouse and human pancreatic organoids to infer resistance to targeted therapy
Presenter: Mariano Ponz-Sarvise
Session: Poster display
Resources:
Abstract
Using diffusion-weighted MRI derived apparent diffusion coefficient as a predictive biomarker of tumor response in non-Hodgkin lymphoma
Presenter: Siarhei Kharuzhyk
Session: Poster display
Resources:
Abstract
Use of treatments of questionable benefit in hospitalized patients with metastatic gastric or esophageal cancer near the end of life. A country-wide, register-based study
Presenter: Emmanuelle Kempf
Session: Poster display
Resources:
Abstract
Use of Oncotype DX Recurrence Score® (RS) reduces chemotherapy (CT) beyond treatment decisions using Ki67-based determinations of luminal A and B breast cancer subtypes: a retrospective study in the Spanish population
Presenter: Laura Garcia-Estevez
Session: Poster display
Resources:
Abstract
Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: interim results of pan-European non-interventional study
Presenter: Petra Pichler
Session: Poster display
Resources:
Abstract
Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC). Part1: the ENCOURAGE cohort of 1158 patients (pts) by GINECO
Presenter: Dominique Berton-Rigaud
Session: Poster Display
Resources:
Abstract
Use and clinical impact of conventional cytotoxic chemotherapy (CTx) subsequent to immunotherapy in metastatic melanoma
Presenter: Eoghan Malone
Session: Poster display
Resources:
Abstract